GLP-3R

Triple Receptor Agonist Pharmacology Research

Receptor-binding and signaling studies characterize GLP-3R as a single peptide that engages GLP-1R, GIPR and GCGR at the same time^[1]. Its potency ordering in cAMP assays (GIPR, then GLP-1R, then GCGR) makes it a model compound for imbalanced multi-receptor agonism, in which potencies at the individual receptors are set at unequal ratios to shape the integrated cellular response. The ratio of receptor potencies is the central design variable across unimolecular agonists at the GIP, GLP-1 and glucagon receptors, a peptide class reviewed by Knerr and colleagues^[5].

The cryo-electron microscopy structures show how one sequence is accommodated by three receptors^[2]. The three complexes are highly similar overall, with Cα root mean square deviations of 0.88 to 0.93 Å. The peptide keeps a common set of contacts with conserved receptor residues, including two salt bridges formed by the N-terminal amine of Tyr1, while receptor-specific contacts in the upper half of the transmembrane pocket absorb the sequence differences between the receptors^[2]. Extracellular loop 1 forms a short α-helix in GLP-1R and GCGR but an unwound loop in GIPR, attributed to three proline residues (P195, P197 and P199). In the GIPR complex the peptide straightens, and the helix at Leu27 shifts about 4 Å toward the transmembrane core relative to the other two complexes^[2].

Alanine mutagenesis in the same study weighed the shared contacts receptor by receptor. Substitution at the conserved E6.53b position lowered cAMP potency 3.6-fold at GLP-1R, 1.6-fold at GIPR and 8.3-fold at GCGR, and substitution at E/D7.42b lowered it 71.6-fold at GIPR and 5.8-fold at GCGR^[2]. The coordinates are public, so the contact map is open to re-analysis by any structural biology group.

Long-Acting Acylated Peptide Engineering Research

GLP-3R is studied in the peptide chemistry literature as a model compound for γGlu-AEEA-C20 fatty diacid acylation at a lysine ε-amine, here Lys-17^[1]. From the lysine outward, the arm runs through a γ-L-glutamic acid spacer and a single 8-amino-3,6-dioxaoctanoic acid (AEEA) unit to a C20 α,ω-eicosanedioic diacid, the moiety that binds serum albumin. Reversible albumin binding is the basis of the extended plasma residency of acylated peptides at the incretin receptors^[3].

Three non-coded residues shape stability and conformation: Aib at positions 2 and 20 and (αS)-α-methyl-leucine at position 13^[1]. Aib at position 2 removes the N-terminal dipeptidyl peptidase IV cleavage site, and the α,α-disubstituted residues at positions 13 and 20 favor the helical conformation seen along the full receptor-bound peptide in the cryo-electron microscopy structures^[2]. Couplings onto and from α,α-disubstituted residues are sterically hindered steps in solid-phase synthesis.

The molecular formula contains no sulfur, so the sequence carries no methionine or cysteine and is not exposed to sulfur-oxidation chemistry. The two aspartate residues, Asp-9 and Asp-15, are the positions at which aspartimide formation, a common side reaction in Fmoc solid-phase synthesis, can occur. Hydrolysis within the lipidation arm is the other principal chemical liability.

The analytical consequence follows from the structure. Receptor activity assays measure signaling, not mass, so they do not by themselves establish that the lipidation arm is intact. Identity at the level of the arm is read by liquid chromatography mass spectrometry with deconvolution, which separates the intact parent from variants missing the C20 diacid, the AEEA unit or the γGlu spacer.

Glucagon Receptor and Hepatic Metabolism Research

The glucagon-receptor arm of GLP-3R is studied as a hepatic signaling axis distinct from the two incretin receptors. GCGR is expressed at high density on hepatocytes. In the broader endocrinology literature, hepatocyte GCGR signaling through Gαs, cAMP and protein kinase A is characterized as activating glycogen phosphorylase and glycogenolysis and inducing gluconeogenic gene expression, and in rodent and isolated-hepatocyte preparations it has been associated with mitochondrial β-oxidation of fatty acids, induction of fibroblast growth factor 21 (FGF21) and lower de novo lipogenesis.

The question specific to unimolecular co-agonism is how the receptor arms interact. GCGR signaling raises hepatic glucose output, while GLP-1R signaling in islet β cells is glucose-dependent and insulinotropic. In the preclinical systems in which GLP-3R was first characterized, GCGR activity was set at about 0.3 times that of native glucagon, and concurrent incretin-receptor activity was described as counterbalancing the glycogenolytic signal of the GCGR arm^[1].

The GCGR complex also differs structurally from the other two^[2]. The extracellular half of transmembrane helix 7 in GCGR shifts outward by about 4.6 Å and 3.0 Å relative to the GLP-1R and GIPR complexes, reorienting the N-terminus of the peptide by about 2.8 Å and 2.6 Å. GLP-1R and GIPR each form two hydrogen bonds with Thr7 and Ser11 of the peptide that GCGR does not, because the equivalent GCGR positions (I194 and S297) cannot form them^[2]. These receptor-specific features make the GCGR arm a structurally defined object of study in its own right.